@article{2aa811a8212144a7914df01ea3c27576,
title = "The importance of the 2S albumins for allergenicity and cross-reactivity of peanuts, tree nuts, and sesame seeds",
abstract = "Allergies to peanuts, tree nuts, and sesame seeds are among the most important food-related causes of anaphylaxis. Important clinical questions include: Why is there a variable occurrence of coallergy among these foods and Is this immunologically mediated? The clinical and immunologic data summarized here suggest an immunologic basis for these coallergies that is based on similarities among the 2S albumins. Data from component resolved diagnostics have highlighted the relationship between IgE binding to these allergens and the presence of IgE-mediated food allergy. Furthermore, in vitro and in vivo experiments provide strong evidence that the 2S albumins are the most important allergens in peanuts for inducing an allergic effector response. Although the 2S albumins are diverse, they have a common disulfide-linked core with similar physicochemical properties that make them prime candidates to explain much of the observed coallergy among peanuts, tree nuts, and sesame seeds. The well-established frequency of cashew and pistachio nut coallergy (64%-100%) highlights how the structural similarities among their 2S albumins may account for observed clinical cross-reactivity. A complete understanding of the physicochemical properties of the 2S albumins in peanuts, tree nuts, and sesame seeds will enhance our ability to diagnose, treat, and ultimately prevent these allergies.",
keywords = "2S albumins, IgE, Peanuts, food allergy, tree nuts",
author = "Dreskin, {Stephen C.} and Koppelman, {Stef J.} and Sandra Andorf and Nadeau, {Kari C.} and Anjeli Kalra and Werner Braun and Negi, {Surendra S.} and Xueni Chen and Schein, {Catherine H.}",
note = "Funding Information: Supported by National Institutes of Health grants R01AI099029 (to S.C.D.), R21AI135397 (to S.C.D.), R21AI137881 (to X.C.), R21 AI109090 and R01 AI 137332 (to W.B.),EPA Star RE-83406601 and US Department of Agriculture – ARS 58-6435-6-40 (to C.H.S.) and a National Institute of Allergy and Infectious Diseases R01 grant ( 5R01 AI140134 [to K.N.]), as well as a grant from the Myra Reinhard Family Foundation (to K.N.). The contents are the sole responsibility of the authors and do not necessarily represent official National Institutes of Health views. Funding Information: Supported by National Institutes of Health grants R01AI099029 (to S.C.D.), R21AI135397 (to S.C.D.), R21AI137881 (to X.C.), R21 AI109090 and R01 AI 137332 (to W.B.),EPA Star RE-83406601 and US Department of Agriculture – ARS 58-6435-6-40 (to C.H.S.) and a National Institute of Allergy and Infectious Diseases R01 grant (5R01 AI140134 [to K.N.]), as well as a grant from the Myra Reinhard Family Foundation (to K.N.). The contents are the sole responsibility of the authors and do not necessarily represent official National Institutes of Health views. Disclosure of potential conflict of interest: S. C. Dreskin reports grant support from Genentech, Inc; in addition, he is a member of the Medical Expert Panel, Department of Health and Human Services, Division of Vaccine Injury Compensation, and serves on an advisory board and/or is a consultant for Allakos, CSL Behring, BioCryst, Grifols, and UKKO. S. Koppelman is a consultant for DBV Technologies. K. C. Nadeau reports grants from the Food Allergy Research and Education, End Allergies Together, Allergenis, and Ukko Pharma, and she is involved in clinical trials with Regeneron, Genentech, AImmune Therapeutics, DBV Technologies, AnaptysBio, Adare Pharmaceuticals, Stallergenes-Greer, Novartis, Sanofi, Astellas, and Nestle. In addition, K. C. Nadeau is a data and safety monitoring board member at Novartis and the National Heart, Lung and Blood Institute; she cofounded BeforeBrands, Alladapt, ForTra, and Iggenix; she is a director of Food Allergy Research and Education and the World Allergy Organization Center of Excellence; and she has received personal fees from Regeneron, AstraZeneca, ImmuneWorks, and Cour Pharmaceuticals. The rest of the authors declare that they have no relevant conflicts of interest. Publisher Copyright: {\textcopyright} 2020 American Academy of Allergy, Asthma & Immunology",
year = "2021",
month = apr,
doi = "10.1016/j.jaci.2020.11.004",
language = "English (US)",
volume = "147",
pages = "1154--1163",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",
}